Literature DB >> 23324661

Persistent immune activation in chronic HIV infection: do any interventions work?

Reena Rajasuriar1, Gabriela Khoury, Adeeba Kamarulzaman, Martyn A French, Paul U Cameron, Sharon R Lewin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23324661      PMCID： PMC4285780          DOI： 10.1097/QAD.0b013e32835ecb8b

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  106 in total

1.  An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Authors:  Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

3.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

4.  ColoPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhoea.

Authors:  Claes-Henrik Florén; Sonny Chinenye; Lidia Elfstrand; Conny Hagman; Ingemar Ihse
Journal:  Scand J Gastroenterol       Date:  2006-06       Impact factor: 2.423

5.  Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation.

Authors:  Collin L Ellis; Zhong-Min Ma; Surinder K Mann; Chin-Shang Li; Jian Wu; Thomas H Knight; Tammy Yotter; Timothy L Hayes; Archana H Maniar; Paolo V Troia-Cancio; Heather A Overman; Natalie J Torok; Anthony Albanese; John C Rutledge; Christopher J Miller; Richard B Pollard; David M Asmuth
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

6.  Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates.

Authors:  Ivona Pandrea; Elaine Cornell; Cara Wilson; Ruy M Ribeiro; Dongzhu Ma; Jan Kristoff; Cuiling Xu; George S Haret-Richter; Anita Trichel; Cristian Apetrei; Alan Landay; Russell Tracy
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

7.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

8.  High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Authors:  Veronica D Gonzalez; Karolin Falconer; Kim G Blom; Olle Reichard; Birgitte Mørn; Alex Lund Laursen; Nina Weis; Annette Alaeus; Johan K Sandberg
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

9.  A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Authors:  Hiroyu Hatano; Rebecca Scherzer; Yuaner Wu; Kara Harvill; Kristinalisa Maka; Rebecca Hoh; Elizabeth Sinclair; Sarah Palmer; Jeffrey N Martin; Michael P Busch; Steven G Deeks; Priscilla Y Hsue
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

10.  CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus.

Authors:  Andrea Kovacs; Lena Al-Harthi; Shawna Christensen; Wendy Mack; Mardge Cohen; Alan Landay
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226
View more
  53 in total

1.  Communicable and non-communicable diseases: connections, synergies and benefits of integrating care.

Authors:  A D Harries; A M V Kumar; S Satyanarayana; Y Lin; K C Takarinda; H Tweya; A J Reid; R Zachariah
Journal:  Public Health Action       Date:  2015-09-21

Review 2.  Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy.

Authors:  Daniela F Passos; Maria Rosa C Schetinger; Daniela Br Leal
Journal:  World J Virol       Date:  2015-08-12

Review 3.  Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.

Authors:  Hugo Ribeiro Zanetti; Leonardo Roever; Alexandre Gonçalves; Elmiro Santos Resende
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

Review 4.  Diagnosis and management of lymphomas and other cancers in HIV-infected patients.

Authors:  Antonino Carbone; Emanuela Vaccher; Annunziata Gloghini; Liron Pantanowitz; Akin Abayomi; Paolo de Paoli; Silvia Franceschi
Journal:  Nat Rev Clin Oncol       Date:  2014-03-11       Impact factor: 66.675

Review 5.  The role of type I interferons in CD4+ T cell differentiation.

Authors:  Mirela Kuka; Marco De Giovanni; Matteo Iannacone
Journal:  Immunol Lett       Date:  2019-02-13       Impact factor: 3.685

6.  Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Authors:  Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

7.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

Review 8.  The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review.

Authors:  Natalie E Kelso; David S Sheps; Robert L Cook
Journal:  Am J Drug Alcohol Abuse       Date:  2015-07-30       Impact factor: 3.829

Review 9.  The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care.

Authors:  Emanuela Vaccher; Diego Serraino; Antonino Carbone; Paolo De Paoli
Journal:  Oncologist       Date:  2014-06-26

10.  Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Authors:  Florin Tuluc; Sergei Spitsin; Nancy B Tustin; Jennifer B Murray; Richard Tustin; Laura A Schankel; Andrew Wiznia; Sharon Nachman; Steven D Douglas
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-18       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.